While bioprinted tissues are ideal for assessing the pharmacology and structural components of disease, they are not high throughput enough for drug screening, medicinal chemistry and large molecule development support. The development and optimization of disease-expressing human primary cell 3D models amenable to screening activities uses multiple proprietary technologies and will provide a key tool that will drive development.
